Seizure Possibly Associated with Fluvoxamine

Kim, Kye Y.; Craig, Janet M; Hawley, Joanne M.

doi:10.1345/aph.10134

Cited by 10 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small studies with a number of other SSRIs have also shown an indication for a possible beneficial effect in some neurological disorders: paroxetine and citalopram in patients with Parkinson's disease (Rampello et al 2002; Chung et al 2005), sertraline in patients with traumatic brain injury (Fann et al 2001), and citalopram and fluvoxamine in patients with epilepsy (Harmant et al 1990; Kim et al 2000; Favale et al 2003; Specchio et al 2004; Nakahira et al 2005). As distinct SSRIs have different affinities for the serotonin receptors, it is not possible to generalize the results of fluoxetine to all other SSRIs.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Potential of Fluoxetine in Neurological Disorders

Mostert

Koch

Heerings

et al. 2008

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

The selective serotonin reuptake inhibitor (SSRI) fluoxetine, which is registered for a variety of psychiatric disorders, has been found to stimulate the cAMP-responsive element binding protein (CREB), increase the production of brain-derived neurotrophic factor (BNDF) and the neurotrophic peptide S100beta, enhance glycogenolysis in astrocytes, block voltage-gated calcium and sodium channels, and decrease the conductance of mitochondrial voltage-dependent anion channels (VDACs). These mechanisms of actions suggest that fluoxetine may also have potential for the treatment of a number of neurological disorders. We performed a Pubmed search to review what is known about possible therapeutic effects of fluoxetine in animal models and patients with neurological disorders. Beneficial effects of fluoxetine have been noted in animal models of stroke, multiple sclerosis, and epilepsy. Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy. Clinical studies so far were small and often poorly designed. Results were inconclusive and contradictory. However, the available preclinical data justify further clinical trials to determine the therapeutic potential of fluoxetine in neurological disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Potential of Fluoxetine in Neurological Disorders

Mostert

Koch

Heerings

et al. 2008

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

show abstract

“…There is limited evidence from the literature that selective serotonin reuptake inhibitors cause seizure exacerbations. There are some isolated reports of seizures in adults treated with fluvoxamine (Kim, Craig, & Hawley, 2000; Trabert, Hohagen, Winkelmann, & Berger, 1995; Deahl & Trimble, 1991) and one case of status epilepticus (Loo, Piau, Galinowski, & Olie, 1987). There is a suggestion that fluoxetine might even have antiepileptic properties (Favale, Rubino, Mainardi, Lunardi, & Albano, 1995), although this has been challenged (Gigli et al., 1994).…”

Section: Part II Epilepsy and Behavioural Disordersmentioning

confidence: 99%

Childhood epilepsy in relation to mental handicap and behavioural disorders

Besag¹

2002

Child Psychology Psychiatry

View full text Add to dashboard Cite

Epidemiological studies indicate that there is a high rate of mental retardation and behavioural problems in children with epilepsy. In some cases both the epilepsy and the mental retardation will have a common cause, such as a metabolic disorder or brain trauma. However, in other children, the epilepsy itself may cause either temporary or permanent learning problems. When permanent learning disability can be prevented it is important to treat the epilepsy early and effectively. Children with specific learning difficulties and memory problems can benefit greatly from appropriate management. There are many causes of behavioural disturbance in children with epilepsy. These causes include the epilepsy itself, treatment of the epilepsy, reactions to the epilepsy, associated brain damage/dysfunction and causes that are equally applicable to children who do not have epilepsy. Identifying the cause or causes in each child allows rational management to be provided. Antiepileptic treatment with medication or surgery can either improve the situation or make matters worse. The treatment should be tailored to the needs of the individual child. If surgery is required, there is a strong argument for performing this early in life, both to allow the greatest opportunity for brain plasticity and also to allow the child full benefit from the important developmental and educational years, without the problems that can be associated with the epilepsy. Skilled management of children with epilepsy who have mental retardation and/or behavioural problems can be very rewarding both for the family and for the professionals involved.

show abstract

“…However, short‐term use for reducing the risk of COVID‐19 infection severity, may most likely be safe. 36 , 37 A scoping review on the exposure of patients to psychotropic drugs reached interesting and congruent results. Bonnet et al 38 reached a conclusion that exposure to SSRI or SNRI drugs may reduce mortality rate of patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, short-term use for reducing the risk of COVID-19 infection severity, may most likely be safe. 36,37 A scoping review on the exposure of patients to psychotropic drugs reached interesting and congruent results.…”

Section: Discussionmentioning

confidence: 99%

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

Firouzabadi

Kheshti

Abdollahifard

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aim Due to the high social and economic burden and also mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few years, researchers have aimed at finding solutions to suppressing the severity of infection. Recently, selective serotonin and serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRI) have been investigated as an adjuvant treatment for COVID‐19. The aim of the current study was to investigate the impact of SSRI/SNRIs on outcomes of COVID‐19 patients. Methods In this systematic review and meta‐analysis, a comprehensive search strategy consisting of relevant words was performed by two researchers in PubMed, Scopus and EMBASE libraries. Studies reporting the effect of SSRI and/or SNRI use in COVID‐19 patients' outcome were included. Hospitalization, mortality, hospitalization event, and length of hospital stay were considered as main outcomes of this study. Analysis was carried out using Comprehensive Meta‐Analysis (CMA‐version 2) and final data were reported as odds ratio (OR) and 95% confidence interval (CI). Results Our search led to the final selection of 9 articles including 15,287 patients. The effect of fluvoxamine, fluoxetine, and the overall effect of SSRI/SNRI use on mortality of COVID‐19 patients were investigated in 3, 2, and 7 articles, respectively. The results of our analyses showed that these medications could significantly decrease mortality of COVID‐19 patients (OR and 95% [CI]: 0.595 [0.467–0.758], 0.620 [0.469–0.821], and 0.596 [0.437–0.813]). The effect of SSRI/SNRIs on hospitalization events of COVID‐19 patients was not significant (OR: 0.240% and 95% CI: 0.041–1.4). Also, length of hospital stay was longer in patients who administrated SSRIs. Conclusion According to this study's results, SSRI/SNRIs may be effective in reducing mortality of COVID‐19 patients, suggesting the superiority of fluvoxamine to fluoxetine. The safety profile and affordable cost of SSRI/SNRIs for a short‐term use may be other reasons to propose them as beneficial medications in preventing mortality in COVID‐19.

show abstract

Seizure Possibly Associated with Fluvoxamine

Abstract: Despite the relatively safe and benign adverse effect profile of the selective serotonin-reuptake inhibitors such as fluvoxamine, clinicians should be cautious about seizures as an adverse effect, especially when the patient has even a remote history of seizure or head trauma.

Cited by 10 publications

References 11 publications

Therapeutic Potential of Fluoxetine in Neurological Disorders

Therapeutic Potential of Fluoxetine in Neurological Disorders

Childhood epilepsy in relation to mental handicap and behavioural disorders

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

Contact Info

Product

Resources

About